Angiotensin II induces reactive oxygen species, DNA damage, and T-cell apoptosis in severe COVID-19.

ACE2 DNA oxidation SARS-CoV-2 angiotensin II receptor antioxidant lymphopenia oxidative stress programmed cell death

Journal

The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002

Informations de publication

Date de publication:
09 2022
Historique:
received: 11 01 2022
revised: 24 04 2022
accepted: 17 06 2022
pubmed: 17 7 2022
medline: 14 9 2022
entrez: 16 7 2022
Statut: ppublish

Résumé

Lymphopenia is predictive of survival in patients with coronavirus disease 2019 (COVID-19). The aim of this study was to understand the cause of the lymphocyte count drop in severe forms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Monocytic production of reactive oxygen species (ROSs) and T-cell apoptosis were measured by flow cytometry, DNA damage in PBMCs was measured by immunofluorescence, and angiotensin II (AngII) was measured by ELISA in patients infected with SARS-CoV-2 at admission to an intensive care unit (ICU) (n = 29) or not admitted to an ICU (n = 29) and in age- and sex-matched healthy controls. We showed that the monocytes of certain patients with COVID-19 spontaneously released ROSs able to induce DNA damage and apoptosis in neighboring cells. Of note, high ROS production was predictive of death in ICU patients. Accordingly, in most patients, we observed the presence of DNA damage in up to 50% of their PBMCs and T-cell apoptosis. Moreover, the intensity of this DNA damage was linked to lymphopenia. SARS-CoV-2 is known to induce the internalization of its receptor, angiotensin-converting enzyme 2, which is a protease capable of catabolizing AngII. Accordingly, in certain patients with COVID-19 we observed high plasma levels of AngII. When looking for the stimulus responsible for their monocytic ROS production, we revealed that AngII triggers ROS production by monocytes via angiotensin receptor I. ROSs released by AngII-activated monocytes induced DNA damage and apoptosis in neighboring lymphocytes. We conclude that T-cell apoptosis provoked via DNA damage due to the release of monocytic ROSs could play a major role in COVID-19 pathogenesis.

Sections du résumé

BACKGROUND
Lymphopenia is predictive of survival in patients with coronavirus disease 2019 (COVID-19).
OBJECTIVE
The aim of this study was to understand the cause of the lymphocyte count drop in severe forms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
METHODS
Monocytic production of reactive oxygen species (ROSs) and T-cell apoptosis were measured by flow cytometry, DNA damage in PBMCs was measured by immunofluorescence, and angiotensin II (AngII) was measured by ELISA in patients infected with SARS-CoV-2 at admission to an intensive care unit (ICU) (n = 29) or not admitted to an ICU (n = 29) and in age- and sex-matched healthy controls.
RESULTS
We showed that the monocytes of certain patients with COVID-19 spontaneously released ROSs able to induce DNA damage and apoptosis in neighboring cells. Of note, high ROS production was predictive of death in ICU patients. Accordingly, in most patients, we observed the presence of DNA damage in up to 50% of their PBMCs and T-cell apoptosis. Moreover, the intensity of this DNA damage was linked to lymphopenia. SARS-CoV-2 is known to induce the internalization of its receptor, angiotensin-converting enzyme 2, which is a protease capable of catabolizing AngII. Accordingly, in certain patients with COVID-19 we observed high plasma levels of AngII. When looking for the stimulus responsible for their monocytic ROS production, we revealed that AngII triggers ROS production by monocytes via angiotensin receptor I. ROSs released by AngII-activated monocytes induced DNA damage and apoptosis in neighboring lymphocytes.
CONCLUSION
We conclude that T-cell apoptosis provoked via DNA damage due to the release of monocytic ROSs could play a major role in COVID-19 pathogenesis.

Identifiants

pubmed: 35841981
pii: S0091-6749(22)00911-3
doi: 10.1016/j.jaci.2022.06.020
pmc: PMC9278992
pii:
doi:

Substances chimiques

Reactive Oxygen Species 0
Angiotensin II 11128-99-7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

594-603.e2

Informations de copyright

Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Auteurs

Lucy Kundura (L)

Institute of Human Genetics, UMR9002, CNRS, Montpellier University, Montpellier, Nîmes, France.

Sandrine Gimenez (S)

Institute of Human Genetics, UMR9002, CNRS, Montpellier University, Montpellier, Nîmes, France.

Renaud Cezar (R)

Immunology Department, Nîmes University Hospital, Nîmes, France.

Sonia André (S)

INSERM U1124, Université Paris Descartes, Paris, France.

Mehwish Younas (M)

Institute of Human Genetics, UMR9002, CNRS, Montpellier University, Montpellier, Nîmes, France.

Yea-Lih Lin (YL)

Institute of Human Genetics, UMR9002, CNRS, Montpellier University, Montpellier, Nîmes, France.

Pierre Portalès (P)

Immunology Department, Montpellier University Hospital, Montpellier, France.

Claire Lozano (C)

Immunology Department, Montpellier University Hospital, Montpellier, France.

Charlotte Boulle (C)

Infectious Diseases Department, Montpellier University Hospital, Montpellier, France.

Jacques Reynes (J)

Infectious Diseases Department, Montpellier University Hospital, Montpellier, France.

Thierry Vincent (T)

Immunology Department, Montpellier University Hospital, Montpellier, France.

Clément Mettling (C)

Institute of Human Genetics, UMR9002, CNRS, Montpellier University, Montpellier, Nîmes, France.

Philippe Pasero (P)

Institute of Human Genetics, UMR9002, CNRS, Montpellier University, Montpellier, Nîmes, France.

Laurent Muller (L)

Surgical Intensive Care Department, Nîmes University Hospital, Nîmes, France.

Jean-Yves Lefrant (JY)

Surgical Intensive Care Department, Nîmes University Hospital, Nîmes, France.

Claire Roger (C)

Surgical Intensive Care Department, Nîmes University Hospital, Nîmes, France.

Pierre-Géraud Claret (PG)

Medical and Surgical Emergency Department, Nîmes University Hospital, Nîmes, France.

Sandra Duvnjak (S)

Gerontology Department, Nîmes University Hospital, Nîmes, France.

Paul Loubet (P)

Infectious Diseases Department, Nîmes University Hospital, Nîmes, France.

Albert Sotto (A)

Infectious Diseases Department, Nîmes University Hospital, Nîmes, France.

Tu-Anh Tran (TA)

Pediatrics Department, Nîmes University Hospital, Nîmes, France.

Jérôme Estaquier (J)

INSERM U1124, Université Paris Descartes, Paris, France; Laval University Research Center, Québec City, Québec, Canada.

Pierre Corbeau (P)

Institute of Human Genetics, UMR9002, CNRS, Montpellier University, Montpellier, Nîmes, France; Immunology Department, Nîmes University Hospital, Nîmes, France. Electronic address: pcorbeau@igh.cnrs.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH